Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Learning disability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Learning disability. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-000389-12 Sponsor Protocol Number: 3.0 Start Date*: 2013-09-11
    Sponsor Name:Cardiff University
    Full Title: ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial
    Medical condition: Aggression and challenging behaviour in adults with learning disabilities
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019519-39 Sponsor Protocol Number: RAPIT Start Date*: 2012-03-14
    Sponsor Name:Erasmus MC - Department of Neurology
    Full Title: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial)
    Medical condition: Tuberous Sclerosis Complex
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000645-14 Sponsor Protocol Number: EFC16035 Start Date*: 2020-10-13
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
    Medical condition: Primary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BG (Trial now transitioned) EE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) LV (Completed) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003410-15 Sponsor Protocol Number: 6251 7976 Start Date*: 2005-11-21
    Sponsor Name:Neurology Unit
    Full Title: A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis.
    Medical condition: Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011228-73 Sponsor Protocol Number: OCTUMI-03 Start Date*: 2010-02-09
    Sponsor Name:University of Oxford [...]
    1. University of Oxford
    2.
    Full Title: A pilot study of Aripiprazole treatment for antipsychotic induced hyperprolactinaemia in young patients with severe mental illness and learning disabilities.
    Medical condition: Antipsychotic induced hyperprolactinaemia
    Disease: Version SOC Term Classification Code Term Level
    12 10020737 Hyperprolactinaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001693-27 Sponsor Protocol Number: 05/Q1606/30 Start Date*: 2005-06-24
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Pilot Effectiveness of Randomised Mandatory Insulin Therapy
    Medical condition: Those admitted to the Intensive Care Unit for treatment and likely to remain on the unit for longer than 5 days.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017581-22 Sponsor Protocol Number: 20091003 Start Date*: 2011-01-04
    Sponsor Name:Department of Psychiatry and Psychotherapy, Charity University Medicine
    Full Title: Cognitive impairment in bipolar disorder treated with aripiprazole
    Medical condition: Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000687-16 Sponsor Protocol Number: ARIDDS2 Start Date*: 2017-12-13
    Sponsor Name:AOU FEDERICO II
    Full Title: Novel avenues for the rescue of intellectual disability in Down syndrome
    Medical condition: DOWN SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10042801 Syndrome Down's LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001317-15 Sponsor Protocol Number: BAL2-2006 Start Date*: 2006-05-09
    Sponsor Name:University of Oxford
    Full Title: BALANCE 2: Bipolar disorder:Antidepressant/Lamotrigine/ANtipsychotic Comparative Evaluation
    Medical condition: Bipolar depression.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004827-44 Sponsor Protocol Number: R&D2008/083 Start Date*: 2008-11-18
    Sponsor Name:King's College London
    Full Title: OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH SPECIAL EDUCATIONAL NEEDS
    Medical condition: We will conduct a prospective, open-label pilot study of atomoxetine targeted toward symptoms of ADHD in children with learning disabilities and ADHD (Attention Deficit Hyperactivity Disorder).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    9.1 10020658 Hyperkinetic syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020154-33 Sponsor Protocol Number: RTG113388 Start Date*: 2012-03-09
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures(≥12 years old) and Subjects with Lennox-Gastaut Syndrome (≥12 ...
    Medical condition: Uncontrolled partial onset seizures or Lennox Gastaut Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    14.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004650-34 Sponsor Protocol Number: GR-2011-02348985 Start Date*: 2016-06-27
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
    Full Title: Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia
    Medical condition: Multiple sclerosis with cerebellar ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002213-19 Sponsor Protocol Number: ELICE-BD-O1 Start Date*: 2019-09-19
    Sponsor Name:University of British Columbia
    Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa...
    Medical condition: Euthymic Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-001496-11 Sponsor Protocol Number: 08020 Start Date*: 2010-01-15
    Sponsor Name:University of Nottingham
    Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple Sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023678-38 Sponsor Protocol Number: GR-2008-1138784 sottostudio Start Date*: 2011-04-20
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy.
    Medical condition: patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002648-10 Sponsor Protocol Number: 7109 Start Date*: 2019-04-15
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000618-32 Sponsor Protocol Number: GNC-501 Start Date*: 2022-09-29
    Sponsor Name:GENEURO SA
    Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy...
    Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10071323 Neuropsychiatric syndrome PT
    20.0 10037175 - Psychiatric disorders 10078497 Neuropsychiatric symptoms PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002790-94 Sponsor Protocol Number: 200828 Start Date*: 2020-09-16
    Sponsor Name:SLSO
    Full Title: The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density – A Single Dose Randomized, Double Blind, Placebo-Controlled Phase 2 Positron Emission Tomography Study
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002395-39 Sponsor Protocol Number: WN43174 Start Date*: 2022-05-24
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-...
    Medical condition: NMDAR or LGI1 mediated autoimmune Encephalitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 06:56:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA